183 related articles for article (PubMed ID: 12806638)
21. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
[TBL] [Abstract][Full Text] [Related]
22. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
Shanahan F
Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
[No Abstract] [Full Text] [Related]
23. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
24. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS
J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974
[No Abstract] [Full Text] [Related]
25. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease.
Ritz MA; Jost R
Inflamm Bowel Dis; 2001 Nov; 7(4):327. PubMed ID: 11720324
[No Abstract] [Full Text] [Related]
26. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy.
Dubcenco E; Ottaway CA; Chen DL; Baker JP
Eur J Gastroenterol Hepatol; 2006 May; 18(5):565-6. PubMed ID: 16607158
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence?
Katsanos KH; Christodoulou DK; Zioga A; Tsianos EV
Inflamm Bowel Dis; 2003 Jul; 9(4):279. PubMed ID: 12902853
[No Abstract] [Full Text] [Related]
28. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease.
Teichgräber U; Atreya I; Atreya R; Schwab M; Neurath MF
Inflamm Bowel Dis; 2013; 19(4):E54-5. PubMed ID: 22532373
[No Abstract] [Full Text] [Related]
29. Episodic retreatment versus scheduled maintenance therapy of crohn's disease with infliximab: not so far apart.
Sartor RB
Gastroenterology; 2004 Feb; 126(2):598-601. PubMed ID: 14762796
[No Abstract] [Full Text] [Related]
30. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist.
Angelucci E; Cocco A; Viscido A; Vernia P; Caprilli R
Inflamm Bowel Dis; 2007 Aug; 13(8):1059-61. PubMed ID: 17387676
[No Abstract] [Full Text] [Related]
31. Pericarditis as a complication of infliximab therapy in Crohn's disease.
Burke JP; Kelleher B; Ramadan S; Quinlan M; Sugrue D; O'Donovan MA
Inflamm Bowel Dis; 2008 Mar; 14(3):428-9. PubMed ID: 17924565
[No Abstract] [Full Text] [Related]
32. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
Kugathasan S
J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975
[No Abstract] [Full Text] [Related]
33. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
34. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
Thomas CW; Weinshenker BG; Sandborn WJ
Inflamm Bowel Dis; 2004 Jan; 10(1):28-31. PubMed ID: 15058523
[TBL] [Abstract][Full Text] [Related]
35. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
Panaccione R; Fedorak RN; Aumais G; Bernstein CN; Bitton A; Croitoru K; Enns R; Feagan B; Fishman M; Greenberg G; Griffiths A; Marshall JK; Rasul I; Sadowski D; Seidman E; Steinhart H; Sutherland L; Walli E; Wild G; Williams CN; Zachos M;
Can J Gastroenterol; 2004 Aug; 18(8):503-8. PubMed ID: 15372114
[No Abstract] [Full Text] [Related]
36. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.
Rampton DS
Gut; 2005 Oct; 54(10):1360-2. PubMed ID: 16113045
[No Abstract] [Full Text] [Related]
37. Severe agranulocytosis following first infliximab infusion in Crohn's disease.
Rosales-Zábal JM; Fernández-Pérez F; Albandea-Moreno C; Vera-Rivero FM; Navarro-Jarabo JM
Inflamm Bowel Dis; 2011 Nov; 17(11):E147-8. PubMed ID: 21830280
[No Abstract] [Full Text] [Related]
38. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
[No Abstract] [Full Text] [Related]
39. Are we giving biologics too late? The case for early versus late use.
Ricart E; García-Bosch O; Ordás I; Panés J
World J Gastroenterol; 2008 Sep; 14(36):5523-7. PubMed ID: 18810770
[TBL] [Abstract][Full Text] [Related]
40. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
